| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0002 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.003 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.099 | 0.003 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.005 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.089 | 0.008 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.09 | 0.009 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.01 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.079 | 0.01 |